Biocon Partners With Biotech Startup In Latest India-U.S. Deal

NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases